Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05224050 · ClinicalTrials.gov registry record · Phase 2
Heart Rate Variability Biofeedback for Smoking Cessation Treatment
A Phase 2 study, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT05224050: Completed Phase 2 study, sponsored by Rutgers, The State University of New Jersey.
NCT05224050 is a Phase 2 study that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 28 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05224050, a Phase 2 study, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of the study is to conduct an open trial examining the feasibility and acceptability of an adapted heart rate variability biofeedback and smoking cessation treatment that was using a primarily virtual remote intervention.
Primary Outcome
Number of intervention sessions attended out of 7 possible sessions.
Interventions
- DRUG Nicotine patch
- BEHAVIORAL Cognitive-Behavioral Smoking Cessation
- BIOLOGICAL Heart Rate Variability Biofeedback
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2021-11-29 |
| Est. Completion | 2023-06-15 |
| Phase | Phase 2 |
What the finished NCT05224050 record still lists
NCT05224050 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 3 interventions - of which Nicotine patch is the first listed.
NCT05224050 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05224050 about?
NCT05224050 is a clinical study titled "Heart Rate Variability Biofeedback for Smoking Cessation Treatment". The purpose of the study is to conduct an open trial examining the feasibility and acceptability of an adapted heart rate variability biofeedback and smoking cessation treatment that was using a primarily virtual remote intervention.
What is the current status of trial NCT05224050?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2021-11-29. Estimated completion is 2023-06-15.
What interventions are being tested in trial NCT05224050?
The interventions under investigation include: Nicotine patch (DRUG), Cognitive-Behavioral Smoking Cessation (BEHAVIORAL), Heart Rate Variability Biofeedback (BIOLOGICAL).
Who is sponsoring clinical trial NCT05224050?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05224050's enrollment target sits among peer trials
28 1677th of 2000 higher than 304 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI